News
AstraZeneca (LSE:AZN) TAGRISSO Shows Clinically Meaningful Survival Improvement In Lung Cancer Study
AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...
Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.
AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...
AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...
AstraZeneca announces $50B US investment by 2030, creating thousands of jobs and building its largest drug manufacturing facility in Virginia.
The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...
Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...
AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...
Virginia facility investment will be AstraZeneca’s largest yet. Maryland, Massachusetts, California, Indiana, Texas projects ...
6d
Clinical Trials Arena on MSNAstraZeneca’s Phase III trial of baxdrostat shows mean SBP reduction
AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.
AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create ...
The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results